Get the Stockscreener App
19.34
3.64%
0.68
After Hours:
19.56
0.22
+1.14%
Forte Biosciences Inc stock is traded at $19.34, with a volume of 45,304.
It is up +3.64% in the last 24 hours and up +42.73% over the past month.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
See More
Previous Close:
$18.66
Open:
$19.07
24h Volume:
45,304
Relative Volume:
0.09
Market Cap:
$123.65M
Revenue:
-
Net Income/Loss:
$-31.48M
P/E Ratio:
-16.67
EPS:
-1.16
Net Cash Flow:
$-28.71M
1W Performance:
-16.46%
1M Performance:
+42.73%
6M Performance:
+54.72%
1Y Performance:
+4.54%
1-Day Range:
$18.00
$19.56
1-Week Range:
$17.50
$23.05
52-Week Range:
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
19.34 | 123.65M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
(FBRX) Long Term Investment Analysis - Stock Traders Daily
Why Forte Biosciences (FBRX) Stock Is Trading Lower - Benzinga
Forte Biosciences, Inc. (NASDAQ:FBRX) Short Interest Update - Defense World
Invea Therapeutics Strengthens Leadership with Appointment of Dr. Stephen Doberstein, Veteran Biotech Executive, to Its Board of Directors - The Manila Times
Trading (FBRX) With Integrated Risk Controls - Stock Traders Daily
FBRX Stock Soars to 52-Week High, Reaching $24.46 By Investing.com - Investing.com Nigeria
Forte Biosciences’ $53 Million Equity Financing - Global Legal Chronicle
(FBRX) Trading Report - Stock Traders Daily
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going - MSN
FBRX Stock Soars to 52-Week High, Reaching $21.47 - Investing.com India
FBRX Stock Soars to 52-Week High, Reaching $21.47 By Investing.com - Investing.com UK
Forte Biosciences Sets R&D Day to Showcase FB102 Autoimmune Treatment Pipeline | FBRX Stock News - StockTitan
Forte Biosciences CFO acquires $124,997 in company stock By Investing.com - Investing.com Canada
Forte Biosciences CFO acquires $124,997 in company stock - Investing.com
More than $50M raised by publicly traded drug developer - The Business Journals
Dallas' Forte Biosciences Announces $53M Private Placement From Leading Healthcare Investors - dallasinnovates.com
Forte Biosciences Stock More Than Doubles On Oversubscribed $53M Private Placement: Retail Goes Wild - MSN
EDIT Stock Drops Amid Market Volatility in Biotech Sector - GuruFocus.com
Cidara’s $100M PIPE; Pyxis Oncology’s stock falls on Phase 1 data - Endpoints News
Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn
Forte Biosciences secures $53 million in funding By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market Acti - GuruFocus.com
Artelo Biosciences (ARTL) Stock Surges Amid Strong Buy Ratings - GuruFocus.com
5 Stocks Retail Investors Are Most Bullish On At Mid-Day - MSN
Forte Biosciences Secures $53M for FB102 Advancements - TipRanks
Terns Pharmaceuticals (TERN) Stock Drops Over 5% Amidst Mixed In - GuruFocus.com
Forte Biosciences Shares Are Soaring Today: What's Going On? - Benzinga
Crude Oil Moves Lower; Williams-Sonoma Shares Gain After Q3 Results - Benzinga
Forte Biosciences secures $53 million in funding - Investing.com India
Forte Biosciences More Than Doubles on $53M Private Placement - MarketWatch
Stock Market News: Forte Biosciences +151.47%, Exicure +99.48% among top gainers during mid day trading - Business Upturn
Stock Market News: Ethan Allen Interiors down by 90.10% while Exicure gains 99.48% during mid day trading - Business Upturn
Nasdaq Tumbles Over 100 Points; TJX Earnings Top Views - Benzinga
Stock Market Today: Forte Biosciences up by 54.60% while Red Cat Holdings gains 35% in early trading - Business Upturn
Stock Market Today: Ethan Allen Interiors falls by nearly 90% while Forte Biosciences surges by 64.89% in early trading - Business Upturn
US Stocks Mostly Lower; Target Posts Downbeat Earnings - Benzinga
Thrive Tribe Technologies Affirms ASX Compliance Amid Stock Query - MSN
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications - The Bakersfield Californian
Forte Biosciences Secures $53M Private Placement for Autoimmune Drug Development | FBRX Stock News - StockTitan
Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
IBD Rating Upgrades: Chesapeake Utilities Flashes Improved Relative Price Strength - MSN
Celiac Disease Pipeline Grows as 25+ Key Pharma Companies Join the Fight for Innovative Treatments | DelveInsight - Lelezard
Forte Biosciences, Inc. announced that it expects to receive $53 million in funding from OrbiMed Advisors LLC, Janus Henderson Group plc, Tybourne Capital Management Limited, Ikarian Capital, LLC, BVF Partners L.P., Fred Alger Management, LLC - Marketscreener.com
When the Price of (FBRX) Talks, People Listen - Stock Traders Daily
Psyence Biomedical gets extension to show compliance with Nasdaq’s listing rules - MSN
Brown Advisory US Smaller Companies PLC Updates Office Location - MSN
Stephens & Co. Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation - MSN
Forte Biosciences (NASDAQ:FBRX) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
Dairy Max Names Agriculture Industry Veteran as its New CEO - dallasinnovates.com
Forte Biosciences Inc reports results for the quarter ended September 30Earnings Summary - XM
Perceptive Advisors LLC Acquires Shares in Forte Biosciences Inc - GuruFocus.com
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Forte Biosciences Inc Stock (FBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '24 |
Option Exercise |
0.00 |
375 |
0 |
8,395 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '24 |
Option Exercise |
0.00 |
1,250 |
0 |
77,568 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jul 01 '24 |
Option Exercise |
0.00 |
9,375 |
0 |
203,849 |
| Wagner Paul A. | SEE REMARKS |
Jul 01 '24 |
Option Exercise |
0.00 |
31,250 |
0 |
1,910,424 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Apr 01 '24 |
Option Exercise |
0.00 |
9,375 |
0 |
197,819 |
| Wagner Paul A. | SEE REMARKS |
Apr 01 '24 |
Option Exercise |
0.00 |
31,250 |
0 |
1,881,627 |
| Chen Hubert C | See remarks |
Jan 01 '24 |
Option Exercise |
0.00 |
7,500 |
0 |
96,478 |
| Riley Antony A | Chief Financial Officer |
Jan 01 '24 |
Option Exercise |
0.00 |
9,375 |
0 |
192,285 |
| Wagner Paul A. | See Remarks |
Jan 01 '24 |
Option Exercise |
0.00 |
31,250 |
0 |
1,854,486 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):